McKesson Corporation (MCK) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions.
Total Revenue Chart for McKesson Corporation
McKesson Corporation (MCK) revenue for FY2026 was USD 403.4B, a 12.4% change from FY2025. McKesson Corporation's revenue grew from USD 13.2B in 1995 to USD 403.4B in 2026 (2958.8% over 31 years). Earnings per share grew from USD 0.65 in 2000 to USD 25.72 in 2025 (3860.0%). Revenue compound annual growth rate: 5-year CAGR of 11.1%, 10-year CAGR of 7.8%, 20-year CAGR of 7.9%.
Total Revenue (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $101.59B
- Implied Share Price
- $871.38
- Enterprise Value
- $101.86B
- Revenue (TTM)
- $403.43B
- EBITDA
- $6.88B
- Profit Margin
- 1.18%
- Trailing P/E
- 22.83
- Forward P/E
- 18.76
- Price/Book (MRQ)
- 4.92
- Price/Sales (TTM)
- 0.25
- EV/EBITDA
- 14.19
- EV/Revenue
- 0.25
- Dividend Yield
- 0.00%
- Book Value
- $-18.10
- Free Cash Flow (FY2026)
- $5.72B
- Free Cash Flow Yield
- 5.63%
Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.